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Propranolol plasma levels and kinetic disposition may be altered
by hypothermic cardiopulmonary bypass (CPB-H). We investigated
the potential influence of obesity on propranolol pharmacokinetics
in patients undergoing coronary artery bypass grafting employing
CPB-H. Fifteen patients, receiving propranolol perorally pre- (10-
40 mg, 2-3 times a day) and post-operatively (10 mg, once a day)
were distributed in two groups, based on body mass index (BMI),
in obese (n = 9, BMI: mean 29.4 kg/m2) and non-obese (n=6, BMI:
mean 24.8 kg/m2). A serial of blood samples was collected at the
pre- and post-operative periods at time dosing interval (τ);
propranolol plasma levels were measured one day before and after
surgery using a high performance liquid chromatographic
procedure described previously. PK Solutions software 2.0 was
applied to obtain pharmacokinetic parameters. No changes on
kinetic parameters as biological half-life (t1/2, p = 0.0625, NS),
volume of distribution (Vd/F, p=0.8438, NS) and plasma clearance
(CLT/F, p = 0.1563, NS) were obtained for the non-obese patients,
while a prolongation of t1/2 (3.2 to 11.2 h, p< 0.0039), an increase
on Vd/F (3.0 to 7.7 L/kg, p<0.0039) and reduction on CLT/F (11.3
to 9.2 mL/min.kg, p<0.0391) were obtained in the post-operative
period for obese patients. Pharmacokinetic data could justify
propranolol plasma concentrations in obese patients higher than
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Propranolol, a nonselective beta-adrenergic
blocking agent, is an usual drug prescribed for treatment
of arterial hypertension, angina pectoris, and cardiac
arrhythmia. It is totally absorbed after the oral dose, shows
a first-pass effect and consequently a low fraction of dose
absorbed reaches the systemic circulation as unchanged
drug. The drug highly distributed, also binds to plasma
proteins, with approximately 90% of the circulating drug
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bounded mainly to plasma α1-acid glycoprotein (Sager et
al., 1989). Additionally, this lipophilic drug is extensively
biotransformed by the liver, with most inactive metabo-
lites excreted in the urine.
High variability in pharmacokinetics of propranolol
reported in normal subjects and also in patients, affecting
mainly distribution and elimination of drug (Jones et al.,
1976; Boudoulas et al., 1978; McAllister et al., 1979;
McAllister et al., 1980; Hoffman, Lefkowitz, 1996)
associated to different response between individuals
related to sympathetic tone (PDR, 1998) could explain the
wide range on plasma levels noted at therapeutic doses
required to reach clinical efficacy.
Propranolol plasma levels appear to be altered in
surgical patients following coronary bypass grafting with
mild hypothermic (~32 °C) cardiopulmonary bypass,
CPB-H, (McAllister et al., 1979; Holley et al., 1982;
Buylaert et al., 1989). Consequently doses could be
adjusted to avoid undesirable consequences in the post-
operative period.
On the other hand, drug prescription for obese
patients is not easy, since changes in dosage scheme,
based on pharmacokinetic data in normal subjects, could
induce errors (Cheymol et al., 1997). Discussion remains,
considering the influence of obesity on kinetics of
propranolol reported previously and also the pharmaco-
kinetic change after cardiopulmonary bypass in non-obese
patients.
Then, a study protocol was designed to investigate
the influence of CPB-H on the kinetic disposition of
propranolol in obese patients with coronary heart disease
indicated for myocardial revascularization with CPB
under moderate hypothermia.
MATERIAL AND METHODS
Fifteen coronarian patients scheduled for myocar-
dial revascularization with moderate hypothermic
(~32 oC) cardiopulmonary bypass were included in the
protocol. The Institutional Ethical Committee (N: 1414/
98/109) previously approved this protocol, and all of the
patients provided written informed consent to participate
in the study. In addition, all procedures were performed in
accordance with institutional guidelines. Ambulatorial
patients (unstable angina) under chronic treatment
receiving propranolol (10-40 mg PO two or three times a
day, for several months) were included. They were
distributed into two groups, obese patients (n = 9) and non-
obese patients (n = 6), based on body mass index (BMI;
reference for obesity >25 kg/m2); additionally body
weight deviation, expressed as percentage of ideal body
weight (reference for obesity >10 %) was also compared
to BMI for all patients.
Characteristics of subjects of both groups, expressed
as the mean (CI 95), are as follows. Obese patients: age:
57 (52-63) yr; body weight: 83 (75-91) kg; height:
168 (161-174) cm; body mass index (BMI): 29.4 (27-32)
kg/m2; body weight deviation: 29.2 (14-44)%; body
surface area (BSA): 1.9 (1.8-2.0) m2. Non-obese patients:
age: 61 (56-65) yr; body weight: 71 (66-76) kg; height:
169 (164-173) cm; BMI: 24.8 (24-25) kg/m2; body weight
deviation: 3.1 (0.7-5.5) %; and BSA: 1.8 (1.7-1.9) m2.
Selected coronary patients were in the infirmary for
routine examination before surgery. A day before the
surgical intervention, in the morning, after drug intake,
pre-operative blood sampling was performed at time dose
interval (zero, 2, 4, 6, and 8 h or 12 h) for pharma-
cokinetics. Then, early next morning, all patients were
submitted to cardiac surgery with CPB - H. At the first
post-operative day, they received propranolol PO dose, 10
mg once a day; blood samples were collected again at time
dose interval (zero, 2, 4, 6, 8, 12 and 24 h) for pharmaco-
kinetics.
Propranolol plasma levels were determined by high
performance liquid chromatography with fluorescence
detection (HPLC-F), as reported previously by Pereira et
al. (2000). Twenty-five microliters of internal standard
(verapamil 2.5 µg/assay), 200 µL of 1.25 N NaOH, and 3
mL of dichloromethane were added to 200 µL of plasma.
Mixture was vortexed for 1 min and centrifuged for 30
min at 3000 rpm. Then, the organic phase was transferred
and evaporated to dryness, and the residue was dissolved
with 100 µL of mobile phase (0.38 M acetate buffer pH
5.0:acetonitrile 65:35, v/v) and injected into the HPLC
system using analytical column (NovaPak C18 150 x
3.9 mm, 5 µm, Waters Assoc., Mildford, USA). Peaks
were monitored using a fluorescence detector setted at 290
nm/358 nm, excitation/emission as described previously.
PK Solutions 2.0 software for pharmacokinetics was
applied to data obtained. Area under the curve (AUCT) and
kinetic parameters obtained from plasma curve decay:
apparent volume of distribution (Vd/F), and drug elimi-
nation measured through total body clearance (ClT/F), and
biological half-life (t1/2), at the pre-operative and post-
operative periods were estimated.
The GraphPad InStatTM (GraphPad Software, San
Diego, USA) was applied to the data obtained for
statistics. Tests for paired and unpaired data were applied
for statistical analysis and data reported in the present
study was expressed as median, mean and CI95 range.
Non parametric tests were applied and a significance
p < 0.05 was considered.
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RESULTS AND DISCUSSION
Pharmacokinetics of propranolol in obesity:
non-obese versus obeses
At the pre-operative period, a slight but non
significant reduction was obtained in plasma clearance
and volume of distribution when obese patients were
compared to the controls, remaining unchanged the
biological half-life. Plasma levels comparing obese and
non-obese patients in this period are showed in Figure 1.
Similar reductions in these parameters were
reported previously for obese individuals versus normal
subjects after IV single dose of propranolol (Cheymol et
al., 1987; Poirier et al., 1990; Cheymol et al., 1997). The
modification of regional blood flow was proposed by
those authors to explain the altered tissue diffusion of drug
in the obese subjects. Additionally, they reported that
lipophilic beta-adrenoceptor blockers as propranolol seem
to diffuse less into adipose than into lean tissues, based
also on several electrical forms present (i.e. cations,
neutral forms, or zwitterions) at physiological pH, that
contribute to their tissue distribution in both obese and
lean subjects. The tissue distribution in obese patients
could be restricted by the sum of hydrophobic forces and
hydrogen bonds they elicit with macromolecules in lean
tissues (Cheymol et al., 1997).
According to Belfrage (1978), in a previous study
carried out in dogs, changes in the vascular resistance of
adipose tissues were induced by the activation of the
sympathetic nerves and noradrenaline administration, as
a consequence of the combined results of alpha-adrenergic
vasoconstriction and beta-adrenergic vasodilatation. The
author also reports that propranolol and practolol
potentiate vasoconstriction induced by noradrenaline
administration or sympathetic nerve stimulation in dogs.
Therefore, it is possible that a vasoconstriction by
beta-blocking drugs in adipose tissue of humans could
restrict the distribution of a highly lipid soluble substance
such as propranolol without modifying the distribution of
hydrophilic drugs as sotalol, because of its weak lipid
solubility (Poirier et al., 1990).
By the other hand, the plasma clearance of a
substance with a high hepatic extraction ratio, such as
propranolol, depends on hepatic blood flow rather than on
the metabolic activity of liver in subjects with normal liver
function (Weiss et al., 1978). Additionally, as commented
by Poirier et al.(1990), the decrease in total body plasma
clearance of propranolol obtained by Braillon and Capron,
(1983) as a consequence of histological hepatic alterations,
could explain the reduction of metabolic capacity in obese
subjects, in spite of routine liver function tests show to be
unaltered in those subjects (Braillon et al., 1985). Therefore,
they proposed that these modifications could be due mainly
to changes in tissue perfusion in obese individuals (Braillon,
Capron, 1983; Braillon et al., 1985)
Pharmacokinetics of propranolol in non-obese patients:
post- versus pre-operative - influence of CPB-H
Pharmacokinetics of propranolol in non-obese
patients remains unchanged after CPB-H as described in
FIGURE 1 - Propranolol plasma levels (means) at the pre-operative period in patients: obeses, n = 9 versus non-obeses,
n = 6.
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Table 1. The high interindividual variation of plasma
clearance, half-life and volume of distribution obtained in
the present study showing non significant alterations, for
non-obese patients after surgery could be supported by
pharmacokinetic data reported previously for propranolol
in healthy volunteers and also in patients after
intravascular or peroral administration of single or chronic
doses (Jones et al., 1976; Boudoulas et al., 1978,
McAllister et al., 1979; McAllister et al., 1980; Hoffman,
Lefkowitz, 1996; Cheymol et al., 1997).
Obeses - influence of CPB-H
In parallel, at the first post-operative day, after the
tracheal extubation and drug intake (propranolol PO dose,
10 mg once a day); significant alterations in the
pharmacokinetics were obtained in obese patients, Table
I. Plasma clearance was reduced from 11.3 mL/min.kg to
9.2 mL/min.kg, p = 0.0391), while volume of distribution
was increased from 3.0 L/kg to 7.7 L/kg, (p = 0.0039);
when periods before and after surgery were compared.
Elimination half-life was prolonged by 3.5 fold (3.2 vs
11.2 h, p = 0.0039); then, it could be justified once non-
proportional alterations were obtained in plasma clearance
and volume of distribution after CPB-H.
Plasma drug concentration at dose interval in the
post-operative period for both groups are illustrated in
Figure 2.
It is well known that a 30% reduction of organ
perfusion after cardiac surgery employing CPB can
TABLE I - Influence of CPB-H on pharmacokinetics of propranolol in obese patients
Kinetic Parameters Non-obese patients – CONTROL, median (CI95%) mean
(reference data 1*) Pre- Post- P
t1/2 (3.9+0.4 h) 3.1 (2.0-7.0) 4.5 7.6 (4.0-11.0) 7.5 0.0625
ClT/F (16+5 mL/min.kg) 17.2 (7.9-35.1) 21.5 9.0 (6.4-14.9) 10.7 0.1563
Vd/F (4.3+0.6 L/kg) 4.6 (1.1-13.9) 7.5 5.9 (3.0-10.9) 6.9 0.8438
Obese patients - median (CI95%) mean
t1/2 (3.9+0.4 h) 3.2 (3.0-5.0) 4.0 11.2 (10.2-17.8) 14.0 0.0039
ClT/F (16+5 mL/min.kg) 11.3 (7.3-19.6) 13.4 9.2 (5.4-12.0) 8.7 0.0391
Vd/F (4.3+0.6 L/kg) 3.0 (1.3-9.4) 5.4 7.7 (5.2-15.9) 10.6 0.0039
Statistics: Wilcoxon’s Test, post- versus pre-operative periods; significance level: p< 0.05; 1* Reference values, Hardman
J.G. et al. (1996).
FIGURE 2 - Propranolol plasma levels (means) at the post-operative period in patients: obeses, n = 9 versus non-obeses,
n = 6.
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influence the elimination of drugs by the liver and
kidneys, with kinetic consequences such as reduction on
total body clearance and prolongation of elimination half-
life (Babka, Pifarré, 1977; Fellander et al., 1996; Holley
et al., 1982). In addition, drug distribution and its
metabolism by the liver are altered by the systemic
cooling during the hypothermic conditions decreasing
volume of distribution and also plasma clearance as
demonstrated in previous studies, (Babka, Pifarré, 1977;
McAllister et al., 1979; Fellander et al., 1996).
Therefore, in obese post surgical patients followed
coronary bypass grafting with mild hypothermia (32 °C)
associated to cardiopulmonary bypass, the pharmaco-
kinetics of propranolol could be influenced by the increase
of diffusion of the lipophilic beta blocking agent to tissues.
These findings could be due to a lower restriction on the
diffusion of this drug to the tissues in the obese subjects
obtained after surgery, justifying the increase in volume of
distribution and the prolongation of biological half-life.
It means that CPB-H could affect the equilibrium of
several electrical forms present as a function of physio-
logical pH after surgery contributing to their tissue
distribution in a higher extension in obese than lean subjects
investigated in the present study. Consequently, propranolol
tissue distribution in obese patients could be restricted,
before surgery, by the sum of hydrophobic forces and
hydrogen bonds as reported previously by Cheymol et
al.(1997). Changes obtained in drug distribution and
elimination for obese patients after CPB-H suggest lower
response to vasoconstriction induced by noradrenaline
administration or sympathetic nerve stimulation potentiated
by propranolol that could justify its influence on the
pharmacokinetics in obese patients after surgery.
Data obtained indicate that CPB-H affects the
pharmacokinetics of propranolol by increase of the
extension of distribution and prolongation of biological
half-life in obese patients, while plasma clearance was
reduced in a lower extension. Pharmacokinetic data could
justify propranolol plasma concentrations in obese
patients higher than in non-obeses, after surgery.
RESUMO
Influência da obesidade na farmacocinética do
propranolol em pacientes submetidos à
revascularização do miocárdio com circulação
extracorpórea
As concentrações plasmáticas e a disposição cinética do
propranolol podem ser alteradas pela circulação
extracorpórea (CEC). Investigou-se a influência da obe-
sidade na farmacocinética do propranolol em pacientes
submetidos à revascularização do miocárdio empregan-
do a CEC. Investigaram-se quinze pacientes, recebendo
cronicamente propranolol no pré- (10-40 mg, 2 a 3 vezes
ao dia PO) e no pós-operatório (10 mg, 1 vez ao dia) sen-
do os mesmos distribuídos em dois grupos: obesos (n = 9,
média 29,4) kg/m2; e não-obesos (n = 6, média 24,8 kg/m2).
Colheram-se amostras seriadas de sangue nos períodos
pré- e pós-operatório (τ); determinaram-se as concentra-
ções plasmáticas do propranolol através da croma-
tografia líquida de alta eficiência. Aplicou-se o software
PK Solutions 2.0 para estimativa dos parâmetros
cinéticos. Não se registrou alteração na farmacocinética
do propranolol avaliada através dos parâmetros meia-
vida biológica (t1/2), volume de distribuição aparente (Vd/F)
e depuração plasmática (CLT/F) no grupo de pacientes
não-obesos, enquanto prolongamento relevante da t1/2 (3,2
para 11,2 h, p<0,0039), aumento no Vd/F (3,0 para
7,7 L/kg, p < 0,0039) e redução no CLT/F (11,3 para
9,2 mL/min.kg, p<0,0391) foram observados no grupo de
pacientes obesos, no pós-operatório de revascularização
do miocárdio empregando circulação extracorpórea e
hipotermia. Os parâmetros farmacocinéticos obtidos po-
deriam justificar as concentrações plasmáticas do
propranolol nos pacientes obesos superiores àquelas ob-
tidas para não obesos após a cirurgia cardíaca.
UNITERMOS: Propranolol. Farmacocinética. Circula-
ção extracorpórea. Obesidade.
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